AlphAIAlphAI — Financial news for AI agents
tradingview.com$NVAX

Novavax 3Q 2026: Revenue $68.3M, EPS ($0.19) — 10-Q Summary

Novavax reported Q3 2026 revenue of $68.3M, down year-over-year, with a net loss of $0.19 per share. Product sales rose to $25.7M, while partner revenue fell to $42.6M. R&D expenses declined to $52.4M. Sanofi's trial triggered a $125M milestone payment in October.

Original reporting
tradingview.com
Published Nov 5, 2026, 1:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Novavax 3Q 2026: Revenue $68.3M, EPS ($0.19) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$NVAXBearishMed
01

Why it matters

The earnings release provides fresh data that could influence NVAX's short‑term price action and sector sentiment.

02

Market read

Primary relevance to NVAX shareholders; secondary relevance to biotech sector investors.

03

What to watch

The $125M Sanofi milestone payment, though not yet received, may provide future upside if recognized.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

Novavax released its Q3 2026 earnings via a 10‑Q filing, detailing revenue, product sales, partner licensing revenue, and cost reductions.

Company-level read

Ticker impact

$NVAXBearishMedium confidence
Context

Novavax filed its Q3 2026 10‑Q reporting $68.3M revenue and a $0.19 loss per share, the first public disclosure of these results.

Expected impact

likely slight downside as investors price in lower revenue and continued loss

Evidence & confidence

Revenue fell year‑over‑year and net loss, though narrower, signals ongoing challenges; no positive catalyst offsetting the miss.

Market effects

Sector

Biotech/ vaccine sector may see modest pressure as a peer reports weaker sales.

Regional

U.S. biotech investors may adjust short‑term positions in NVAX.

Global

Limited to investors tracking vaccine developers and biotech earnings.

Counterpoint

What could challenge this read

The narrowed loss could be seen as a step toward profitability, offering a buying opportunity if the market overreacts.

Key entities

  • Company
    Novavax Inc.

    Biotech firm developing vaccine technologies.

  • Partner
    Sanofi

    Pharmaceutical partner providing licensing revenue.

Read at source← All news

StoryNovavax Raises 2026 Revenue Guidance After Sanofi Vaccine Milestone

Also covered by

5 outlets

Related articles

$NVAXMed

Novavax Q3 Earnings Call Highlights

Novavax reported Q3 revenue of $68M, down from $70M YoY, with a net loss of $31M, improved from a $202M loss last year. The company reduced expenses by 41% YoY and expects its cash runway to extend into 2029. Novavax plans to start clinical testing for its C. diff vaccine candidate in 2027 and is exploring oncology applications for its Matrix-M adjuvant. The company aims to reduce expenses to $150M-$200M by 2028.

finance.yahoo.com
$NVAXMed

Novavax (NVAX) Q3 2026 Earnings Call Transcript

Novavax (NVAX) reported Q3 2026 earnings, highlighting a $125 million milestone from Sanofi's phase III trial of a combination flu-COVID vaccine. The company expects additional milestones and revenue from partnerships. Novavax also plans to advance its C. diff vaccine candidate and expand into oncology. The company raised its full-year revenue outlook and improved expense guidance.

finance.yahoo.com
$NVAXHighAI 8/10

Novavax Beats On A Narrower Loss And Lifts Its Outlook On Sanofi's $125 Million Milestone, But Its Profitability Target Slides To 2029

Novavax reported a narrower-than-expected Q3 loss of $0.19 per share, beating estimates by $0.18, with revenue of $68.3M, exceeding expectations by $17.7M. The company raised its full-year revenue outlook to $400M, including a $125M milestone from Sanofi. However, profitability is now expected in 2029, pushed back from 2028, due to delayed milestones and reduced recurring revenue.

finviz.com